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Invariant natural killer T (iNKT) cells are innate-like T lymphocytes. They quickly respond to
antigenic stimulation by producing copious amounts of cytokines and chemokines. iNKT
precursors differentiate into three subsets iNKT1, iNKT2, and iNKT17 with specific
cytokine production signatures. While key transcription factors drive subset
differentiation, factors that regulate iNKT subset homeostasis remain incompletely
defined. Transcriptomic analyses of thymic iNKT subsets indicate that Serpinb1a is one
of the most specific transcripts for iNKT17 cells suggesting that iNKT cell maintenance
and function may be regulated by Serpinb1a. Serpinb1a is a major survival factor in
neutrophils and prevents cell death in a cell-autonomous manner. It also controls
inflammation in models of bacterial and viral infection as well as in LPS-driven
inflammation. Here, we examined the iNKT subsets in neutropenic Serpinb1a−/− mice
as well as in Serpinb1a−/− mice with normal neutrophil counts due to transgenic re-
expression of SERPINB1 in neutrophils. In steady state, we found no significant effect of
Serpinb1a-deficiency on the proliferation and numbers of iNKT subsets in thymus, lymph
nodes, lung, liver and spleen. Following systemic activation with a-galactosylceramide,
the prototypic glycolipid agonist of iNKT cells, we observed similar serum levels of IFN-g
and IL-4 between genotypes. Moreover, splenic dendritic cells showed normal
upregulation of maturation markers following iNKT cell activation with a-
galactosylceramide. Finally, lung instillation of a-galactosylceramide induced a similar
recruitment of neutrophils and production of iNKT-derived cytokines IL-17, IFN-g, and IL-4
in wild-type and Serpinb1a−/− mice. Taken together, our results indicate that Serpinb1a,
while dominantly expressed in iNKT17 cells, is not essential for iNKT cell homeostasis,
subset differentiation and cytokine release.
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Invariant natural killer T (iNKT) cells are tissue resident innate-
like T lymphocytes that respond to lipid antigens. Upon T cell
receptor (TCR) activation, they promptly release cytokines that
modulate inflammation and adaptive responses. In addition,
iNKT cells contribute to tissue homeostasis in the thymus
medulla and in the periphery (1). The TCR of iNKT cells is
specific for exogenous and endogenous lipid antigens presented
by CD1d, a non-polymorphic MHC class I-like molecule. This
specificity is mediated by their semi-invariant TCR composed of
an invariant TCRa chain (Va14-Ja18 in mice, Va24-Ja18 in
humans) paired with a limited set of TCRb chains (Vb2, Vb7, or
Vb8 in mice, Vb11 in humans) (2). iNKT cell development in the
thymus initially overlaps with that of conventional T cells until
the double negative (CD4negCD8neg) stage 4 (DN4). However,
iNKT cells differ from conventional T cells by expressing the
transcription factor PLZF, which is common to innate-like T
cells (3, 4). The majority of iNKT cells proceed to the double
positive stage (DP, CD4+CD8+) and they are selected following
strong interactions with other DP thymocytes expressing CD1d
in the thymus medulla (5–7). Yet, one subset of iNKT cells
differentiates already at the double negative (DN) stage and
remains CD4neg (8).
iNKT cells migrate from the thymus to peripheral organs,
where they are found both as DN as well as CD4+CD8neg in
mouse peripheral organs. As mostly tissue resident cells, their
localization within different organs influences cytokine
production and pathophysiological processes (9). Mature iNKT
cells are classified into functionally heterogeneous subsets
described as iNKT1, iNKT2, and iNKT17, named by analogy
to T helper cells. Differential expression levels of PLZF and of
subset-specific transcription factors distinguish the iNKT1
expressing T-bet and low levels of PLZF; the iNKT2 expressing
GATA-3 and high level of PLZF; and iNKT17 expressing ROR-gt
and intermediate levels of PLZF (10–12). The signature cytokines
of each of the three subsets are IFN-g, IL-4, and IL-17,
respectively (13, 14). Peptide MHC-dependent ab T helper
cells also produce these cytokines but require much more time
for activation, proliferation and differentiation. iNKT cells in
contrast can immediately produce large amounts of these key
cytokines, which potentiate innate immunity and guide adaptive
responses (13). iNKT cell expression of IL-4 and IL-13 appears
essential in mouse models of airway inflammation and hyper-
reactivity and there is some evidence that iNKT cells contribute
to the pathogenesis of human asthma (15). IL-4 produced by
iNKT cells was shown on the contrary to help resolution of sterile
injury in the liver (16) and iNKT cells help reduce tumor growth
and angiogenesis in different types of cancer by releasing INF-g
(17, 18). In models of Streptococcus pneumoniae lung infection,
iNKT cells enhance bacterial clearance by producing IFN-g and
IL-17 and inducing the essential recruitment of neutrophils (19,
20). On the other hand, IL-17 produced by iNKT cells drives the
inflammation in the joints of spondyloarthritis patients (21). A
better understanding of molecular mechanisms that help fine
tuning differentiation and cytokine production by iNKT cells isFrontiers in Immunology | www.frontiersin.org 2needed. The iNKT17 subset, in particular, is not as well defined
as the iNKT1 and iNKT2 (22).
Transcriptomic studies revealed that Serpinb1a gene is highly
and specifically expressed in the iNKT17 subset of both C57BL/6
and BALB/c mouse strains (23, 24). Moreover, the percentage of
iNKT17 cells defined as CD138+ was increased in thymus and lung
of Serpinb1a−/− (Sb1a−/−) mice (24).Whether Serpinb1a contributes
to iNKT cell development, differentiation and function was not
explored. Serpinb1a belongs to the serpin superfamily of protease
inhibitors. Serpinb1a, as its human ortholog SERPINB1, is
expressed in many leukocytes and is particularly abundant in the
neutrophil cytoplasm. It is one of the best inhibitors of the main
neutrophil serine proteases, cathepsin G, neutrophil elastase, and
proteinase 3. Serpinb1a is a survival factor in neutrophils and
monocytes by inhibiting cathepsin G-mediated cell-autonomous
death. Sb1a−/− mice also produce more inflammatory cytokines in
response to infection and endotoxin challenge. We thus explored
here an essential function for Serpinb1 in iNKT cell subset
differentiation and cytokine production.METHODS
Mice
C57BL/6J (WT) breeder mice were from the Janvier Laboratories
(France). Serpinb1atm1.1Cben (Sb1a−/−) mice generated in 129S6/
SvEvTac (129S6) and backcrossed in C57BL/6J background were
described previously (25, 26). Transgenic mice expressing
human SERPINB1 in neutrophils B6J-Tg(S100A8-hSERPINB1)
3Cben (denoted SB1PMN.Tg) were crossed with Sb1a−/− as
described previously (27). All experimental mice were therefore
in the same C57BL/6J and produced in the SPF mouse unit of the
Institute of Virology and Immunology. Mice were used between
8 and 25 weeks and were age- and sex-matched between
genotypes for each experiment. Animal experimentation was
conducted in compliance with the Swiss Animal Welfare
legislation and animal studies were reviewed and approved by
the commission on animal experiments of the canton of Bern,
Switzerland under licenses BE8/16 and BE35/19.Blood and Tissue Leukocyte Isolation
Mice were euthanized and blood was collected in EDTA.
Thymus, lungs, spleen, liver, and lymph nodes (inguinal,
brachial, and axillary) were collected in cold PBS without
cations supplemented with 1% FBS. Single cell suspensions of
lymphoid organs and liver were obtained by successively passing
diced tissue through 70- and 40-µm cell strainers. Liver cell
suspensions were layered over 3 ml of lympholyte M solution
and centrifuged at 1,000 g for 20 min at room temperature. Red
blood cell lysis was performed on spleen and liver cells using
ammonium chloride. Bronchoalveolar lavage fluid (BAL) was
collected by three successive instillation of 1-ml PBS.
Supernatant of the first BAL was used for cytokine
quantification. The pellet was combined with cells of the otherNovember 2020 | Volume 11 | Article 562587
Leborgne et al. Serpinb1a in iNKT Cellstwo BAL and processed for flow cytometry analysis. Cells were
counted in a hemocytometer using Türk’s solution.Flow Cytometry and Cytokine
Measurements
BV421-labelled CD1d tetramers preloaded with PBS57 (PBS57-
tet) and unloaded CD1d tetramers were obtained from the
National Institutes of Health tetramer core facility. Unloaded
control tetramer was used as a negative control for each
experiment. Fluorescently-labelled antibodies against mouse
CD4 (clone RM4-5), CD122 (clone TM-b1), Ki-67 (clone
16A8), T-bet (clone 4B10), and PLZF (clone 9E.12) were from
Biolegend and against CD3 (clone 145-2C11), TCRb (clone
H57-597), and RORgt (clone Q31-378) were from BD
Biosciences. Dead cells were excluded with 7-AAD or LIVE/
DEAD fixable Aqua Dead stain kit (ThermoFisher Scientific,
L34957). Blocking was done with CD16/CD32 (clone 2.4G2,
Biolegend) prior to staining with cell surface antibodies. When
required, cells were subsequently fixed and permeabilized using
the Foxp3 staining buffer (BD biosciences) and incubated for
detection of transcription factors and or proliferation (Ki-67,
EdU). Acquisition of data was performed on a FACS-Canto II
(BD Biosciences) and analyzed with FlowJo software version 10.
Cytokines in BAL, cell supernatants and serum were measured
by ELISA against IFN-g, IL-4 (R&D Systems), and IL-
17A (Invitrogen).In Vivo and In Vitro Models of Inflammation
Stock solutions of a-galactosyceramide (aGalCer) (Sigma,
67576) were prepared in DMSO at 1 mg/ml and stored at
−20°C. For systemic activation, stock aGalCer was pre-diluted
at 0.2 mg/ml in PBS containing 0.02% Tween 20 and further
diluted 1:10 in PBS. Mice were injected intravenously in the tail
vein with 2 µg aGalCer in 100 µl. For local lung inflammation,
stock aGalCer was pre-diluted at 0.5 mg/ml in PBS with 0.02%
Tween 20 and further diluted 1:5 in PBS. Mice were anesthetized
with ketamine and xylazine (100 mg/kg and 10mg/kg,
respectively) and intranasally instilled with 2µg aGalCer in 20
µl. In some experiments, the thymosine analog EdU (5-ethynyl-
2’-deoxyuridine) was injected intravenously (160 µg in 100 µl/
mouse) at the same time as aGalCer stimulation. Total lung cells
were isolated using the mouse Lung Dissociation kit (Milneyi
Biotec, 130-095-927) and proliferating (EdU+) iNKT cells were
detected by flow cytometry using Click-iT EdU Cell Proliferation
Kit (ThermoFisher Scientific, C10337). In vitro cytokine
production was measured in the supernatant of isolated
splenocytes (25 × 106cells/ml) following a 48-h stimulation
with indicated concentrations of aGalCer.Statistical Analysis
Statistical analysis was performed using Prism 8.0 (GraphPad,
San Diego, CA). Mann-Whitney or one-way ANOVA were usedFrontiers in Immunology | www.frontiersin.org 3to compare data from two or three genotypes, respectively. P <
0.05 was considered statistically significant.RESULTS
To investigate whether Serpinb1a contributes to iNKT cell
development and homeostasis, we analyzed iNKT cell subsets
in WT, Sb1a−/− and Sb1a−/−.SB1PMNTg (TG) mice. The latter are
constitutively deficient in endogenous mouse Serpinb1a and
express human SERPINB1 in neutrophils, which rescues the
neutropenic phenotype of Sb1a−/− mice (Figure 1A), as
described previously (27). Percentage and absolute numbers of
iNKT cells (PBS57-tet+) were similar in thymus and spleen of the
different genotypes (Figures 1B, C). In contrast, we found an
increase in absolute numbers of lung iNKT cells of Sb1a−/− mice,
however the percentage of iNKT cells relative to T cells was
comparable between wild-type and Sb1a−/− mice (Figures 1B, C).
Percentage of iNKT cells in liver and lymph node iNKT cells were
also similar in all genotypes (Figure 1C).
Analysis of iNKT subsets were first identified by differential
expression of the surface markers CD4 and CD122 (Figure 2A).
The percentage—but not absolute numbers—of iNKT17
(CD4negCD122neg) cells were significantly increased in the thymus
of Sb1a−/− mice compared to WT (P = 0.01) but not compared to
Sb1a−/−.SB1PMNTg mice (P = 0.1) (Figure 2B). The numbers and
percentages of iNKT17 (CD4negCD122neg) cells in spleen, liver,
lungs, and lymph nodes of Sb1a−/− mice were normal (Figures
2C–F). No difference between genotypes was observed for iNKT1
and iNKT2 numbers and proportions in all the tissues (Figure 2).
Because the delineation of the subsets is ambiguous using cell
surface expression of CD4 and CD122 (Figure 2A), we further
examined iNKT cell subsets in thymus, spleen lung, and lymph
nodes using expression of the nuclear factors PLZF, T-bet, and
RORgt, which provide a particularly clear identification of the
iNKT17 cells (Figure 3A) (28). Using this analysis, percentages
of iNKT17 cells were found to be identical in all genotypes in the
different organs. Absolute numbers of iNKT17 cells but not other
subsets were increased in lungs of Sb1a−/− mice and were similar
in all other tissue (Figures 3B–E). We evaluated iNKT cell basal
proliferation in the various organs by expression of Ki-67 at
steady state. We found no difference between genotypes in Ki-
67+ cells in total iNKT nor in the iNKT17 subset in any organ
(Figure 3F). Overall, these findings do not support evidence for
an essential function of Serpinb1a in iNKT17 cell subset
homeostasis in steady state.
We then investigated iNKT activation in vivo following
intravenous injection of a-galactosylceramide (aGalCer), the
prototypic glycolipid activator of iNKT cells. aGalCer induced
high levels of IFNg and IL-4 in serum of WT and Sb1a−/− mice
(Figure 4A). In contrast, induction of circulating IL-17A was not
detected. We also observed that CD11c+ dendritic cells were
similarly activated in the spleen of WT and Sb1a−/− mice at 4h
and 24 h post-injection of aGalCer as indicated by increased
expression of CD40, CD80, and CD86 (Figure 4B). Cell surfaceNovember 2020 | Volume 11 | Article 562587
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comparable manner in both genotypes at 4 and 24 h (Figure
4C). Therefore, Serpinb1a does not alter the strength of the
response of iNKT cells or their ability to induce dendritic cell
maturation in the spleen following systemic activation by aGalCer.
In vitro, splenocytes of WT and Sb1a−/− mice were stimulated with
increasing concentrations of aGalCer and cytokines were measured
in supernatant after 48 h. A similar dose-dependent induction of IL-
17A was measured in splenocytes of both genotypes (Figure 4D).
iNKT cells are present in the lung parenchyma and local
instillation of aGalCer in the airways has been shown to induce
neutrophil recruitment via IL-17 produced by NKT cells (29, 30).
It was further shown that the RORgt+ iNKT17 subset was theFrontiers in Immunology | www.frontiersin.org 4specific source of the cytokine (28). To investigate the function of
Serpinb1a in a lung model of local inflammation, we measured
neutrophil recruitment, cytokine expression in BAL and iNKT
proliferation 24 h after intranasal instillation of aGalCer (Figure
5A). We observed a similar recruitment of neutrophils and
monocytes in the BAL of WT and Sb1a−/− mice (Figure 5B).
Furthermore, expression of IL-17, IFNg, and IL-4 in BAL were
identical between genotypes (Figure 5C). Finally, total iNKT and
iNKT17 proliferation in lungs (EdU+ and Ki-67+ cells) were
equivalent in WT and Sb1a−/− mice (Figures 5D, E). Taken
together, our results indicate that Serpinb1a does not
significantly modify the inflammatory reaction induced by
activation of lung iNKT cells.A B
C
FIGURE 1 | Ablation of Serpinb1a does not alter iNKT numbers in thymus and periphery. (A) Analysis of bone marrow neutrophils (Ly6G+). (B) Percentages of iNKT
cells (CD1d-PBS57+, TCRb/CD3+) in the thymus, spleen, liver, lung and lymph nodes. (C) Absolute numbers of iNKT cells in the thymus, spleen and lung. Data were
from groups of 6- to 25-week-old mice matched for sex and age between genotypes. Data are from at least five independent experiments. Values for individual mice
are shown with median and interquartile range.November 2020 | Volume 11 | Article 562587
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Two independent transcriptomic studies have identified Serpinb1a
as a gene highly, and specifically expressed in thymic iNKT17 cells
using different cell surface marker strategies (23, 24). Here, we
found that the percentages of iNKT17 cells defined as
CD4negCD122neg were increased in thymus of Sb1a−/− mice.
This finding was reminiscent of the data of Georgiev andFrontiers in Immunology | www.frontiersin.org 5colleagues showing that the percentage of CD138+ (iNKT17)
cells was increased in thymus and lung of Sb1a−/− mice (24).
However, a clear identification of iNKT subsets using cell surface
markers remains challenging (31, 32) and is somewhat subjective
because of the non-binary expression of the markers (Figure 2A).
When we discriminated iNKT subsets using differential expression
of transcription factors, we found no difference in thymus RORgt+
iNKT17 cells between genotypes. Furthermore, proportions ofA D
B E
C F
FIGURE 2 | Surface marker expression analysis of iNKT subsets shows increased thymic iNKT17 cells in Sb1a−/− mice. (A) Representative flow cytometry plots of iNKT cell
subsets based on CD122 and CD4 expression on CD1d-tet+ iNKT cells. Percentages and numbers of iNKT17, iNKT1, and iNKT2 in thymus (B), spleen (C), liver (D), lung (E),
and lymph nodes (F) of mice of the indicated genotypes. Data were from groups of 6-25 week-old mice matched for sex and age between genotypes. Data are from at least
four independent experiments. Values for individual mice are shown with median and interquartile range.November 2020 | Volume 11 | Article 562587
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Sb1a−/− mice using differential expression of CD4/CD122 or of
transcription factors. In the lungs, absolute numbers – but not
percentages – of total iNKT and of iNKT17 cells were increased in
Sb1a−/−mice, a reflection of slightly increased total cell numbers. If
this effect is biologically relevant, the lack of increased iNKT and
iNKT17 cells in Sb1a−/−.SB1PMNTg mice indicate that the effect
would not be iNKT cell-intrinsic and likely dependent on
neutropenia. Proliferation of iNKT and iNKT17 cells was also
similar in both genotypes. Taken together, these data indicate that
deletion of Serpinb1a does not specifically promote RORgt+
iNKT17 subset differentiation, survival or migration relative to
other subsets in steady state conditions. On the contrary, it is
possible that Serpinb1a expression is regulated by RORgt. ThisFrontiers in Immunology | www.frontiersin.org 6hypothesis is supported by the transcriptomic studies of Mucosal
Associated T (MAIT) cells that identified Serpinb1a as a marker
for the MAIT17 subset defined by high expression levels of RORgt
(33, 34). Overall, Serpinb1a expression in innate T cells is
upregulated with or by RORgt and is associated with cells
producing IL-17.
Serpinb1a is a survival factor for neutrophils and a regulator
of inflammation. Sb1a−/− mice are neutropenic despite
expressing 4-fold higher basal levels of G-CSF in blood (35).
They consequently fail to clear Pseudomonas aeruginosa
infection and present severe lung infection with high levels of
TNFa and IL-1b (26). Sb1a−/− mice develop a more pronounced
and protracted inflammation following influenza A virus





FIGURE 3 | Transcription factor expression analysis of iNKT subsets indicates normal thymic iNKT17 cells in Sb1a−/− mice. (A) Representative flow cytometry plots of iNKT
cell subsets based on PLZF, T-bet and RORgt expression on CD1d-tet+ iNKT cells. (B) Percentages and numbers of iNKT17, 1 and 2 in thymus (B), spleen (C), lung (D), and
lymph nodes (E). Percentages of total iNKT and iNKT17 Ki-67+ cells in indicated organs. (F) Data were from groups of 6- to 8-week-old mice matched for sex and age
between genotypes. Data are from at least four independent experiments. Values for individual mice are shown with median and interquartile range.November 2020 | Volume 11 | Article 562587
Leborgne et al. Serpinb1a in iNKT Cellslungs (36). Similarly, systemic inflammation induced by LPS also
causes increased cytokine production in Sb1a−/− mice (37, 38).
Here, we found that local instillation of aGalCer in the lungs
yielded normal production and of IL-4, IFNg and IL-17 in BAL.
These data suggest again that the modest increase iNKT and
iNKT17 cells in the lungs of Sb1a−/− mice had no functional
impact on IL-17 production. Similarly, splenocyte cultures
pulsed with aGalCer also showed a normal IL-17 release.
Finally, spleen dendritic cells were similarly activated in
response to systemic injection of aGalCer in Sb1a−/− and WT
mice. Induction of IL-4 and IFNg in plasma was also comparable
in both genotypes indicating that Serpinb1a is not essential for
this activation pathway in dendritic cells and iNKT cells.Frontiers in Immunology | www.frontiersin.org 7Although Serpinb1a appears as a strong marker for iNKT17 and
MAIT17 cells, we have shown that Serpinb1a is dispensable for
iNKT cell development and differentiation into the iNKT17 subset.
We have also shown that Serpinb1a does not enhance nor impair
dendritic cell-mediated activation of cytokine production by iNKT
cells following stimulation with aGalCer. iNKT cells have a broad
range of actions and act differently depending on the tissue or the
context of infection. It remains possible that, in a more complex
activation setting with multiple stimuli and/or pathogens,
Serpinb1a contributes to altered inflammatory responses in iNKT
cells but this remains to be shown. In conclusion, Serpinb1a is not
essential for homeostasis and aGalCer-induced responses of iNKT
cells and particularly those of iNKT17 cells.A
B
C D
FIGURE 4 | Normal cytokine release following systemic or in vitro activation of iNKT cells by aGalCer in Sb1a−/− mice. (A–C) WT and Sb1a−/− mice (6–8 weeks old)
were injected intravenously with aGalCer. (A) Serum cytokine levels were measured by ELISA at indicated time points. (B) Dendritic cell expression of co-stimulatory
molecules CD40, CD80, and CD86 and (C) antigen presenting molecules CD1d and MHCII were measured by flow cytometry (MFI, mean fluorescence intensity).
Data from three independent experiments; n = 6–12/genotype. (D) Analysis of WT and Sb1a−/− splenocytes stimulated with indicated concentrations of aGalCer.
IL-17, IFNg, and IL-4 levels were measured by ELISA in the supernatant after 48 h. Data were from groups of 6- to 8-week-old mice matched for sex and age
between genotypes. Data are from four independent experiments. Values for individual mice are shown as mean and SEM.November 2020 | Volume 11 | Article 562587
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(A–C) Data are from three independent experiments. Values for individual mice are shown with mean.November 2020 | Volume 11 | Article 562587
Leborgne et al. Serpinb1a in iNKT CellsREFERENCES
1. Wang H, Hogquist KA. How Lipid-Specific T Cells Become Effectors: The
Differentiation of iNKT Subsets. Front Immunol (2018) 9:1450. doi: 10.3389/
fimmu.2018.01450
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol
(2007) 25:297–336. doi: 10.1146/annurev.immunol.25.022106.141711
3. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The
transcription factor PLZF directs the effector program of the NKT cell lineage.
Immunity (2008) 29(3):391–403. doi: 10.1016/j.immuni.2008.07.011
4. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The
BTB-zinc finger transcriptional regulator PLZF controls the development of
invariant natural killer T cell effector functions. Nat Immunol (2008) 9
(9):1055–64. doi: 10.1038/ni.1641
5. Shissler SC, Webb TJ. The ins and outs of type I iNKT cell development. Mol
Immunol (2019) 105:116–30. doi: 10.1016/j.molimm.2018.09.023
6. Dashtsoodol N, Bortoluzzi S, Schmidt-Supprian M. T Cell Receptor Expression
Timing and Signal Strength in the Functional Differentiation of Invariant Natural
Killer T Cells. Front Immunol (2019) 10:841. doi: 10.3389/fimmu.2019.00841
7. Egawa T, Eberl G, Taniuchi I, Benlagha K, Geissmann F, Hennighausen L,
et al. Genetic evidence supporting selection of the Valpha14i NKT cell lineage
from double-positive thymocyte precursors. Immunity (2005) 22(6):705–16.
doi: 10.1016/j.immuni.2005.03.011
8. Dashtsoodol N, Shigeura T, Aihara M, Ozawa R, Kojo S, Harada M, et al.
Alternative pathway for the development of Valpha14(+) NKT cells directly
from CD4(-)CD8(-) thymocytes that bypasses the CD4(+)CD8(+) stage. Nat
Immunol (2017) 18(3):274–82. doi: 10.1038/ni.3668
9. Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. Tissue-
Specific Distribution of iNKT Cells Impacts Their Cytokine Response.
Immunity (2015) 43(3):566–78. doi: 10.1016/j.immuni.2015.06.025
10. Park JY, DiPalma DT, Kwon J, Fink J, Park JH. Quantitative Difference in PLZF
Protein Expression Determines iNKT Lineage Fate and Controls Innate CD8 T Cell
Generation. Cell Rep (2019) 27(9):2548–57 e4. doi: 10.1016/j.celrep.2019.05.012
11. Constantinides MG, Bendelac A. Transcriptional regulation of the NKT cell
lineage. Curr Opin Immunol (2013) 25(2):161–7. doi: 10.1016/j.coi.2013.01.003
12. KimEY, Lynch L, Brennan PJ, CohenNR, BrennerMB. The transcriptional programs
of iNKT cells. Semin Immunol (2015) 27(1):26–32. doi: 10.1016/j.smim.2015.02.005
13. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate
activation scheme linked to diverse effector functions. Nat Rev Immunol
(2013) 13(2):101–17. doi: 10.1038/nri3369
14. Bennstein SB. Unraveling Natural Killer T-Cells Development. Front
Immunol (2017) 8:1950. doi: 10.3389/fimmu.2017.01950
15. Victor JR, Lezmi G, Leite-de-Moraes M. New Insights into Asthma
Inflammation: Focus on iNKT, MAIT, and gammadeltaT Cells. Clin Rev
Allergy Immunol (2020). doi: 10.1007/s12016-020-08784-8
16. Liew PX, Lee WY, Kubes P. iNKT Cells Orchestrate a Switch from
Inflammation to Resolution of Sterile Liver Injury. Immunity (2017) 47
(4):752–65 e5. doi: 10.1016/j.immuni.2017.09.016
17. Crowe NY, Smyth MJ, Godfrey DII. A critical role for natural killer T cells in
immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med
(2002) 196(1):119–27. doi: 10.1084/jem.20020092
18. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, et al.
IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-
cell ligand, alpha-galactosylceramide. Blood (2002) 100(5):1728–33. doi:
10.1182/blood.V100.5.1728.h81702001728_1728_1733
19. Ivanov S, Fontaine J, Paget C, Macho Fernandez E, Van Maele L, Renneson J,
et al. Key role for respiratory CD103(+) dendritic cells, IFN-gamma, and IL-17
in protection against Streptococcus pneumoniae infection in response to alpha-
galactosylceramide. J Infect Dis (2012) 206(5):723–34. doi: 10.1093/infdis/jis413
20. Nakamatsu M, Yamamoto N, Hatta M, Nakasone C, Kinjo T, Miyagi K, et al.
Role of interferon-gamma in Valpha14+ natural killer T cell-mediated host
defense against Streptococcus pneumoniae infection in murine lungs.
Microbes Infect (2007) 9(3):364–74. doi: 10.1016/j.micinf.2006.12.003
21. Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, et al.
RORgammat inhibition selectively targets IL-17 producing iNKT and
gammadelta-T cells enriched in Spondyloarthritis patients. Nat Commun
(2019) 10(1):9. doi: 10.1038/s41467-018-07911-6
22. Tsagaratou A. Unveiling the regulation of NKT17 cell differentiation and
function.Mol Immunol (2019) 105:55–61. doi: 10.1016/j.molimm.2018.11.013Frontiers in Immunology | www.frontiersin.org 923. Engel I, Seumois G, Chavez L, Samaniego-Castruita D,White B, Chawla A, et al.
Innate-like functions of natural killer T cell subsets result from highly divergent
gene programs. Nat Immunol (2016) 17(6):728–39. doi: 10.1038/ni.3437
24. Georgiev H, Ravens I, Benarafa C, Forster R, Bernhardt G. Distinct gene
expression patterns correlate with developmental and functional traits of
iNKT subsets. Nat Commun (2016) 7:13116. doi: 10.1038/ncomms13116
25. Baumann M, Pham CT, Benarafa C. SerpinB1 is critical for neutrophil
survival through cell-autonomous inhibition of cathepsin G. Blood (2013)
121(19):3900–7, S1-6. doi: 10.1182/blood-2012-09-455022
26. Benarafa C, Priebe GP, Remold-O’Donnell E. The neutrophil serine protease
inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa
infection. J Exp Med (2007) 204(8):1901–9. doi: 10.1084/jem.20070494
27. Burgener SS, Baumann M, Basilico P, Remold-O’Donnell E, Touw IP,
Benarafa C. Myeloid conditional deletion and transgenic models reveal a
threshold for the neutrophil survival factor Serpinb1. Biol Chem (2016) 397
(9):897–905. doi: 10.1515/hsz-2016-0132
28. Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, Dy M,
et al. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-
producing invariant NKT cell differentiation. Proc Natl Acad Sci USA (2008)
105(50):19845–50. doi: 10.1073/pnas.0806472105
29. Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB, et al.
Identification of an IL-17-producing NK1.1(neg) iNKT cell population
involved in airway neutrophilia. J Exp Med (2007) 204(5):995–1001.
doi: 10.1084/jem.20061551
30. Lee KA, Kang MH, Lee YS, Kim YJ, Kim DH, Ko HJ, et al. A distinct subset of
natural killer T cells produces IL-17, contributing to airway infiltration of
neutrophils but not to airway hyperreactivity. Cell Immunol (2008) 251(1):50–
5. doi: 10.1016/j.cellimm.2008.03.004
31. Dai H, Rahman A, Saxena A, Jaiswal AK, Mohamood A, Ramirez L, et al.
Syndecan-1 identifies and controls the frequency of IL-17-producing naive
natural killer T (NKT17) cells in mice. Eur J Immunol (2015) 45(11):3045–51.
doi: 10.1002/eji.201545532
32. Cameron G, Godfrey DII. Differential surface phenotype and context-
dependent reactivity of functionally diverse NKT cells. Immunol Cell Biol
(2018). doi: 10.1111/imcb.12034
33. Salou M, Legoux F, Gilet J, Darbois A, du Halgouet A, Alonso R, et al. A
common transcriptomic program acquired in the thymus defines tissue
residency of MAIT and NKT subsets. J Exp Med (2019) 216(1):133–51.
doi: 10.1084/jem.20181483
34. Koay HF, Su S, Amann-Zalcenstein D, Daley SR, Comerford I, Miosge L, et al.
A divergent transcriptional landscape underpins the development and
functional branching of MAIT cells. Sci Immunol (2019) 4(41):1–16.
doi: 10.1126/sciimmunol.aay6039
35. Benarafa C, LeCuyer TE, Baumann M, Stolley JM, Cremona TP, Remold-
O’Donnell E. SerpinB1 protects the mature neutrophil reserve in the bone
marrow. J Leukoc Biol (2011) 90(1):21–9. doi: 10.1189/jlb.0810461
36. Gong D, Farley K, White M, Hartshorn KL, Benarafa C, Remold-O’Donnell E.
Critical role of serpinB1 in regulating inflammatory responses in pulmonary
influenza infection. J Infect Dis (2011) 204(4):592–600. doi: 10.1093/infdis/
jir352
37. Burgener SS, LeborgneNGF, Snipas SJ, SalvesenGS, Bird PII, Benarafa C. Cathepsin
G Inhibition by Serpinb1 and Serpinb6 Prevents Programmed Necrosis in
Neutrophils and Monocytes and Reduces GSDMD-Driven Inflammation. Cell
Rep (2019) 27(12):3646–56 e5. doi: 10.1016/j.celrep.2019.05.065
38. Choi YJ, Kim S, Choi Y, Nielsen TB, Yan J, Lu A, et al. SERPINB1-mediated
checkpoint of inflammatory caspase activation. Nat Immunol (2019) 20
(3):276–87. doi: 10.1038/s41590-018-0303-zConflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Leborgne, Taddeo, Freigang and Benarafa. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.November 2020 | Volume 11 | Article 562587
